This study is in progress, not accepting new patients
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc.
- ID
- NCT04999020
- Phase
- Phase 2/3 Dermatomyositis Research Study
- Study Type
- Interventional
- Participants
- Expecting 150 study participants
- Last Updated